<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04701476</url>
  </required_header>
  <id_info>
    <org_study_id>LT-007</org_study_id>
    <secondary_id>KEYNOTE-A91</secondary_id>
    <nct_id>NCT04701476</nct_id>
  </id_info>
  <brief_title>TATE and Pembrolizumab (MK3475) in mCRC and NSCLC</brief_title>
  <official_title>An Open Label Phase II Study for the Treatment of Liver Metastatic Colorectal Cancer and Non-Small Cell Lung Cancer With a Combination of TATE (Trans-Arterial Tirapazamine Embolization) and Pembrolizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teclison Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Teclison Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with&#xD;
      liver metastasis treated with Trans-arterial Tirapazamine Embolization along with&#xD;
      Pembrolizumab.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open-label single-arm study to treat patients with refractory metastatic&#xD;
      colorectal cancer and non-small cell lung cancer with liver metastasis. Patients' metastatic&#xD;
      liver lesions will be treated with Trans-arterial Tirapazamine Embolization (TATE) for&#xD;
      maximal tumor debulking along with IV injection of Pembrolizumab every three weeks until&#xD;
      disease progression or maximally two years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label, single-arm in two disease indications</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>24 months</time_frame>
    <description>per RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>24 months</time_frame>
    <description>per RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>24 months</time_frame>
    <description>in TATE treated or TATE-untreated lesions by RECIST and mRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>24 months</time_frame>
    <description>Progression Free Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTP</measure>
    <time_frame>24 months</time_frame>
    <description>Time to Progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>36 months</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Colorectal Cancer; Lung Cancer</condition>
  <arm_group>
    <arm_group_label>colorectal cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>metastatic colorectal cancer progressed on at least two lines of chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NSCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liver metastatic NSCLC progressed on immune checkpoint inhibitors and chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TATE and pembrolizumab</intervention_name>
    <description>All liver metastatic lesions will be treated with TATE for maximally debulking. Pembrolizumab IV infusion every 3 weeks until progression or maximally 2 years.</description>
    <arm_group_label>NSCLC</arm_group_label>
    <arm_group_label>colorectal cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Liver metastatic MSS-mCRC or NSCLC without EGFR or AKT mutations&#xD;
&#xD;
          -  mCRC progressed on at least two lines of standard chemotherapy; or&#xD;
&#xD;
          -  NSCLC progressed on chemotherapy and an immune checkpoint inhibitor&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior organ transplantation&#xD;
&#xD;
          -  Liver metastasis more than 50%&#xD;
&#xD;
          -  Oxygen saturation less than 92% in room air&#xD;
&#xD;
          -  Prior autoimmune disorder&#xD;
&#xD;
          -  CNS metastasis&#xD;
&#xD;
          -  Major GI bleeding in the last 2 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ray Lee</last_name>
    <role>Study Director</role>
    <affiliation>Teclison Limited</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ray Lee, MD. PhD.</last_name>
    <phone>8043341076</phone>
    <email>ray.lee01@teclison.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UC Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Duong</last_name>
      <email>duongca@hs.uci.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jasmine Balangue</last_name>
      <email>balanguj@hs.uci.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>China Medical University Hsinchu Hospital</name>
      <address>
        <city>Hsinchu</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>sandy Lai</last_name>
      <email>sandy6618@teclison.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chung Shan Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandy Lai</last_name>
      <email>sandy6618@teclison.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 6, 2021</study_first_submitted>
  <study_first_submitted_qc>January 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2021</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colorectal cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>pembrolizumab</keyword>
  <keyword>tirapazamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>International meeting report or medical Journal publication</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

